Regeneron Pharmaceuticals’ Phase II antibody cocktail REGN1908-1909 in cat-allergic patients with mild asthma had an eight-point increase in its FDA likelihood of approval (LoA) to 18% as of 2 March. The surge is due to the proof-of-concept Phase II REGN1908-1909 trial meeting its primary efficacy endpoint, as per a 27 February media release.
Prior to Phase II data reveal, REGN1908-1909 previously had an LoA of 10%, according to GlobalData analysis using a combination of machine learning and its proprietary algorithm. The 56-patient, placebo-controlled Phase II trial investigated single-dose, 600mg REGN1908-1909, which is administered subcutaneously. The trial met its primary endpoint of preventing early asthma reactions (EAR) with a 12-week assessment period. EAR is defined as a ≥20% decline in forced expiratory volume over one second (FEV1).
REGN1908-1909 features two monoclonal IgG antibodies designed to bind and block Fel d 1 allergens, and so prevents the allergen from triggering endogenous antibodies that causes allergies. Fel d 1 is the major allergen in cat dander. Regeneron has a $50.75bn market cap.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataReynald Castaneda is an Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.
